Outsourcing of Early Discovery Chemistry Experiences to be Discussed By 7 Pharma Giants at Conference & Expo From October 25-27, Long Branch, NJ
LONG BRANCH, N.J., Aug. 30 /PRNewswire/ -- Early discovery chemistry outsourcing experiences will be discussed by the pharmaceutical giants Bristol-Myers Squibb, Pharmacia Corporation, SmithKline Beecham, Glaxo Wellcome, Pfizer Global Research, Ann Arbor Labs, and DuPont Crop Protection at "Outsourcing Discovery Chemistry & Chemical Development Services" in Long Branch, NJ, from October 25-27, announces Strategic Research Institute.
The meeting, the fourth in the series since July/99, will be broadly attended by the pharmaceutical, fine chemical, CRO, and biotech communities.
To register, please call 212.967.0095, x232; the fee is $1295.
To request additional information and/or book your hotel room, contact Anit Hora at ahora@srinstitute.com or 212-967-0095, x261. NO ROOM RESERVATIONS MAY BE MADE DIRECTLY BY CONTACTING THE HOTEL. Please include email and snail mail addresses to expedite your request.
The early discovery outsourcing talks are as follow:
-- Outsourcing Custom Synthesis Supporting Early Discovery
Mark Creswell, Pfizer Global Research, Ann Arbor Laboratories
-- Building a Collection of Novel, Non-Commercially Available Monomers by
Outsourced Custom Synthesis Duncan Judd, Glaxo Wellcome - UK
-- Technical Aspects of Outsourcing Combinatorial Chemistry
Mike Howard, DuPont Crop Protection
-- Procuring Compounds and Combinatorial Libraries from External Sources
Richard Thomas, Pharmacia Corporation
-- A Global Strategy to Develop a Primary Screening Deck
Michael Sofia, Bristol-Myers Squibb
-- Compound Acquisition: Where Have We Been & Where Do We Go Next?
David Langley, Glaxo Wellcome - UK
The early conference sponsor and exhibition list includes ChemFirst, Organix, Gateway Chemical, Array BioPharma, ArQule, MediChem Life Sciences, Camitro Corporation, Trega Bioscience, Engineered Tecnologies, Pharmacopeia, Peakdale Fine Chemicals, and CarboGen.
The full agenda is as follows:
-- Chemical Outsourcing Trends Panel Discussion: A View from The Street
Moderator, Stefan Loren, Legg Mason
-- Outsourcing Custom Synthesis Supporting Early Discovery
Mark Creswell, Pfizer Global Research, Ann Arbor Laboratories
-- Building a Collection of Novel, Non-Commercially Available Monomers by
Outsourced Custom Synthesis
Duncan Judd, Glaxo Wellcome - UK
-- Technical Aspects of Outsourcing Combinatorial Chemistry
Mike Howard, DuPont
-- The Novartis-Vertex Drug Discovery Collaboration
Roger Tung, Vertex Pharmaceuticals
-- The Pfizer - ArQule Drug Research & Technology Licensing Agreement
Sheila Dewitt, ArQule, Inc.
-- Outsourcing Natural Products Discovery: Biodiversity, Combinatorial
Biosynthesis and Libraries for Rapid Hit Prioritization & Lead
Identification, Steve Wrigley, Terragen, Inc. - UK
-- Procuring Compounds from and Combinatorial Libraries from External
Sources
Richard Thomas, Pharmacia Corporation
-- A Global Strategy to Develop a Primary Screening Deck
Mike Sofia, Bristol-Myers Squibb
-- External Compound Acquisition: Where Do We Go From Here?
David Langley, Glaxo Wellcome - UK
Panel on Intellectual Property
Moderated by Tom Saunders, Lorusso & Loud, Boston
-- Enhanced Innovation in Drug Discovery Through Chemical Outsourcing,
Kevin Koch, Array BioPharma
-- Outsourcing ADME/TOX/PK Assays
CEREP
-- The Whole Enchilada: Outsourcing of Proprietary Lead Discovery &
Optimization
Jonathan Burnbaum, Pharmacopeia
-- Outsourcing Chemistry to Pharma & Non-Pharma
Lew Makings, Aurora Biosciences
-- Outsourcing IT and Software Development to Accelerate Drug Discovery
Trevor Heritage, Tripos
-- Panel Discussion on Lead Discovery & Optimization
Moderated by Mike Howard, DuPont Crop Protection
Panelists: Oxford Asymmetry, Bristol-Myers Squibb, Hoffmann-La Roche,
Pfizer Global Research, Ann Arbor Laboratories, MediChem Life Sciences,
Glaxo Wellcome, Pharmacia Corporation
-- Implementing the Best Pharma - CRO Business Model
Moderator: John Budzinski, DuPont Pharmaceuticals
-- Case Study in Chemical Development Outsourcing
Abbott Laboratories
-- Outsourcing of Process Chemistry for Early Drug Candidates
Jolanta Nowakowski, Pfizer, Groton
-- Outsourcing of Bulk Actives: A Biotech Perspective
Jack Regan, Genentech
-- Panel on Outsourcing Chemical Development Services
Moderated by Michael Kolb, Wyeth Ayerst;
Panelists: Pfizer, Bristol-Myers Squibb, Merck & Company, Abbott Labs,
Schering Plough, Eli Lilly, Pharm-Eco Labs, Genentech
-- Outsourcing Process Research & Development at Eli Lilly
Thomas Eckrich, Eli Lilly & Company
QA Assurance and Chemical Development Outsourcing
Carl Rifino, AstraZeneca Pharmaceuticals
-- Small Company Outsourcing Manufacture of Final Product
Matt Hulbert, Cephalon
-- Chemical Outsourcing Regulatory (TBA)
SOURCE Strategic Research Institute
CO: Strategic Research Institute; Bristol-Myers Squibb; Pharmacia Corporation; SmithKline Beecham; Glaxo Wellcome; Pfizer Global Research; Ann Arbor Labs; DuPont Crop Protection
ST: New Jersey
IN: MTC
SU: TDS
08/30/2000 09:28 EDT prnewswire.com |
